top of page
Expertise
VIA / cubeRBQM Performance
78%
57%
19%
19%
By Therapeutic Area
KOR
JPN
Phase II
4%
Ophthalmology
17%
EU
5%
10%
5%
Phase III
10%
Gastroenterology
By Country
Phase IV
10%
Cardiovasular
OS/PMS
24%
Hematology
Medical Device
ETC.
By Phase
Endocrinology
19%
Allergology
5%
4%
Pulmonology
5%
10%
ETC.
eConsent Performance
43%
15%
By Therapeutic Area
KOR
JPN
14%
14%
Phase I
Phase III
14%
43%
Ophthalmology
57%
15%
OS/PMS
14%
Cardiovascular
By Phase
Neurology
Food & supplementary
IIT
Allergology
43%
ETC.
By Country
14%
14%
2025.10 Now
Partnerships
Spero's business partners range from local and overseas clinical trial sponsors, pharmaceutical and medical device companies, to CROs and clinical research sites and centers
Key fields of cooperation
-
Clinical development operation (CRO service)
-
Patient recruitment service support
-
DCT solution operation support
Site Management & Monitoring
Vaccines & Infectious disease
Dentistry
PMS
3%
Phase IV
3%
Achievement
Spero started patient recruitment service in 2021 and has been accumulating achievements in various CRO service areas since it expanded its business to DCT in 2022.
Therapeutic Area & Phase
Experienced Staffs and Potential expertise
Spero is enhancing its expertise and operational efficiency for the successful execution of clinical trials
43%
Ophthalmology
Gastroenterology
Endocrinology
Cardiovascular
Pulmonology
Hematology
5%
5%
8%
8%
11%
24%
By Therapeutic area
By Phase
Others
Medical Device
IIT
OS
Phase I
Phase III
Phase II
3%
5%
14%
5%
14%
Neurology
11%
8%
5%
11%
Clinical Operation
Full Support Service
Spero supports all phases of clinical trials, and prioritizes customer requirements, and the safety of clinical trials
14%
14%
29%
31%
6%
6%
Statistics
Data Management
Medical Writing
Project Management
Site Startup
By Operation service
*Site Management : VIA/cubeRBQM service included.
3%
3%
PMS
Phase IV
Others
14%
bottom of page